Evidera Inc., Waltham, MA, USA.
Pfizer Ltd, Surrey, UK.
Future Oncol. 2019 Feb;15(6):663-681. doi: 10.2217/fon-2018-0512. Epub 2018 Nov 19.
To evaluate the comparative efficacy and safety of gemtuzumab ozogamicin + daunorubicin-cytarabine (GO + DA) versus common induction therapies for newly diagnosed acute myeloid leukemia. Materials & methods: A network meta-analysis following a systematic literature review.
In base-case analyses, GO + DA was associated with significantly greater overall survival and relapse-free survival versus most comparators, and similar rates of complete remission versus all evaluated comparators. Similar findings were seen in the subgroup analyses. Grade 3+ bleeding and hepatic events were higher with GO + DA versus some comparators, consistent with GO's profile. No differences were found for other evaluated outcomes.
GO + DA provides significant overall survival and relapse-free survival benefit versus evaluated induction regimens for newly diagnosed acute myeloid leukemia.
评估吉妥珠单抗奥唑米星联合柔红霉素-阿糖胞苷（GO+DA）与新诊断的急性髓系白血病的常规诱导疗法相比的疗效和安全性。
一项系统文献回顾后的网络荟萃分析。
在基准分析中，GO+DA 与大多数对照相比，具有显著更高的总生存率和无复发生存率，与所有评估的对照相比，完全缓解率相似。亚组分析也得出了类似的结果。GO+DA 组的 3 级以上出血和肝脏事件发生率高于某些对照，与 GO 的作用模式一致。其他评估结果则无差异。
GO+DA 与新诊断的急性髓系白血病的评估诱导方案相比，提供了显著的总生存率和无复发生存率获益。
